US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5656295A
(en)
*
|
1991-11-27 |
1997-08-12 |
Euro-Celtique, S.A. |
Controlled release oxycodone compositions
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5681585A
(en)
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
IL119660A
(en)
*
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP0647448A1
(de)
*
|
1993-10-07 |
1995-04-12 |
Euroceltique S.A. |
Oral verabreichbare, Opioid-Analgetika enthaltende Arzneimittel mit verlängerter Wirkung
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US6210714B1
(en)
*
|
1993-11-23 |
2001-04-03 |
Euro-Celtique S.A. |
Immediate release tablet cores of acetaminophen having sustained-release coating
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US5965161A
(en)
*
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5558879A
(en)
*
|
1995-04-28 |
1996-09-24 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
EA001773B1
(ru)
*
|
1996-03-08 |
2001-08-27 |
Нюкомед Данмарк А/С |
Пероральная фармацевтическая форма лекарственного препарата в виде множественной дозированной формы с модифицированным высвобождением
|
WO1997045091A2
(en)
*
|
1996-05-31 |
1997-12-04 |
Euro-Celtique, S.A. |
Sustained release oxycodone formulations with no fed/fast effect
|
JPH1050306A
(ja)
*
|
1996-07-31 |
1998-02-20 |
Toyota Autom Loom Works Ltd |
水素吸蔵合金電極の製造方法
|
DE19710008A1
(de)
*
|
1997-03-12 |
1998-09-17 |
Basf Ag |
Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
|
RS49982B
(sr)
*
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
CA2314896C
(en)
*
|
1997-12-22 |
2005-09-13 |
Euro-Celtique, S.A. |
A method of preventing abuse of opioid dosage forms
|
PT1685839E
(pt)
|
1997-12-22 |
2013-07-08 |
Euro Celtique Sa |
Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
IL128818A0
(en)
*
|
1998-03-12 |
2000-01-31 |
Akzo Nobel Nv |
Making dosage units using low shear granulation
|
EP0955048A1
(de)
*
|
1998-03-12 |
1999-11-10 |
Akzo Nobel N.V. |
Herstellung von Dosiereinheiten unter Anwendung einer Granulierung mit geringer Scherbeanspruchung
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
EP2269587A1
(de)
*
|
1999-10-29 |
2011-01-05 |
Euro-Celtique S.A. |
Hydrocodon-Formulierungen mit gesteuerter Freisetzung
|
AU2277101A
(en)
*
|
1999-12-20 |
2001-07-03 |
Schering Corporation |
Stable extended release oral dosage composition
|
SK287105B6
(sk)
|
1999-12-20 |
2009-12-07 |
Schering Corporation |
Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
|
HUP0204163A2
(hu)
|
2000-02-08 |
2003-04-28 |
Euro-Celtique S.A. |
Opioid agonistát és antagonistát tartalmazó szabályozott leadású készítmény és eljárás az előállítására
|
AU2738302A
(en)
|
2000-10-30 |
2002-05-15 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
US20030065002A1
(en)
|
2001-05-11 |
2003-04-03 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant controlled-release opioid dosage form
|
CA2449519A1
(en)
*
|
2001-06-08 |
2002-12-19 |
Endo Pharmaceuticals, Inc. |
Controlled release dosage forms using acrylic polymer, and process for making the same
|
PL207748B1
(pl)
*
|
2001-07-06 |
2011-01-31 |
Penwest Pharmaceuticals Company |
Preparat o przedłużonym uwalnianiu zawierający oksymorfon oraz jego zastosowanie
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
CA2452874A1
(en)
*
|
2001-07-06 |
2003-01-16 |
Endo Pharmaceuticals, Inc. |
Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
|
PT1416842E
(pt)
|
2001-07-18 |
2009-03-31 |
Euro Celtique Sa |
Composições farmacêuticas de oxicodona e naloxona
|
PL367427A1
(en)
|
2001-08-06 |
2005-02-21 |
Euro-Celtique S.A. |
Opioid agonist formulations with releasable and sequestered antagonist
|
WO2003015531A2
(en)
*
|
2001-08-06 |
2003-02-27 |
Thomas Gruber |
Pharmaceutical formulation containing dye
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
US20040234602A1
(en)
|
2001-09-21 |
2004-11-25 |
Gina Fischer |
Polymer release system
|
US20040253310A1
(en)
|
2001-09-21 |
2004-12-16 |
Gina Fischer |
Morphine polymer release system
|
US20030091635A1
(en)
*
|
2001-09-26 |
2003-05-15 |
Baichwal Anand R. |
Opioid formulations having reduced potential for abuse
|
PE20030527A1
(es)
*
|
2001-10-24 |
2003-07-26 |
Gruenenthal Chemie |
Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
|
CA2475441C
(en)
*
|
2002-02-21 |
2011-07-05 |
Otsuka Pharmaceutical Co., Ltd. |
Sustained release preparations and process for producing the same
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
SI2425824T1
(sl)
|
2002-04-05 |
2017-06-30 |
Mundipharma Medical Cee Gmbh |
Farmacevtski pripravek, ki vsebuje oksikodon in nalokson
|
CN1665482A
(zh)
*
|
2002-04-29 |
2005-09-07 |
阿尔扎公司 |
羟可待酮控制输送给药的方法和剂型
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
WO2003101384A2
(en)
*
|
2002-05-31 |
2003-12-11 |
Alza Corporation |
Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
US8840928B2
(en)
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US8557291B2
(en)
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
US20040058946A1
(en)
*
|
2002-07-05 |
2004-03-25 |
Buchwald Stephen L. |
Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
CA2491572C
(en)
*
|
2002-07-05 |
2010-03-23 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
US7168140B2
(en)
*
|
2002-08-08 |
2007-01-30 |
Milliken & Company |
Flame resistant fabrics with improved aesthetics and comfort, and method of making same
|
CA2495182A1
(en)
*
|
2002-08-15 |
2004-02-26 |
Noramco, Inc. |
Oxycodone-hydrochloride polymorphs
|
CA2498798A1
(en)
*
|
2002-09-20 |
2004-04-01 |
Alpharma, Inc. |
Sustained-release opioid formulations and methods of use
|
HUE038446T2
(hu)
|
2002-09-20 |
2018-10-29 |
Alpharma Pharmaceuticals Llc |
Szekvesztráló alegység és releváns kompozíciók és módszerek
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
US9107804B2
(en)
*
|
2002-12-10 |
2015-08-18 |
Nortec Development Associates, Inc. |
Method of preparing biologically active formulations
|
JP4865330B2
(ja)
|
2002-12-13 |
2012-02-01 |
デュレクト コーポレーション |
経口ドラッグデリバリーシステム
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
EP1782834A3
(de)
*
|
2003-03-13 |
2007-08-01 |
Controlled Chemicals, Inc. |
Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
|
DE602004024963D1
(de)
|
2003-03-13 |
2010-02-25 |
Controlled Chemicals Inc |
Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
|
ATE495732T1
(de)
|
2003-03-26 |
2011-02-15 |
Egalet As |
Morphin-system mit kontrollierter freisetzung
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
CA2519556C
(en)
|
2003-04-21 |
2011-01-18 |
Benjamin Oshlack |
Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
|
WO2004100929A1
(en)
|
2003-05-12 |
2004-11-25 |
Synergia Pharma, Inc. |
Threo-dops controlled release formulation
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
EP2279729B1
(de)
*
|
2003-07-17 |
2016-08-17 |
Banner Life Sciences LLC |
Zubereitungen mit kontrollierter Freisetzung
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
CA2534925A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Gruenenthal Gmbh |
Dosage form that is safeguarded from abuse
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE102004020220A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
US20050053659A1
(en)
*
|
2003-09-10 |
2005-03-10 |
Pace Gary W. |
Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
|
CA2541371C
(en)
*
|
2003-10-03 |
2014-12-16 |
Atul M. Mehta |
Extended release formulations of opioids and method of use thereof
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
US20070269505A1
(en)
*
|
2003-12-09 |
2007-11-22 |
Flath Robert P |
Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same
|
US8883204B2
(en)
*
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
GB0403098D0
(en)
|
2004-02-12 |
2004-03-17 |
Euro Celtique Sa |
Extrusion
|
TWI350762B
(en)
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
CN1938004B
(zh)
|
2004-03-30 |
2011-12-21 |
欧洲凯尔特公司 |
包含吸附剂和不利剂的抗篡改剂型
|
TW201509943A
(zh)
*
|
2004-03-30 |
2015-03-16 |
Euro Celtique Sa |
含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
|
US20050226929A1
(en)
*
|
2004-04-12 |
2005-10-13 |
Jianbo Xie |
Controlled release opioid analgesic formulation
|
EP1604667A1
(de)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung des Restless Leg Syndroms
|
EP1604666A1
(de)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
|
WO2005123042A1
(en)
*
|
2004-06-10 |
2005-12-29 |
Glatt Air Techniques, Inc. |
Controlled release pharmaceutical formulation
|
EP3326617A1
(de)
|
2004-06-12 |
2018-05-30 |
Collegium Pharmaceutical, Inc. |
Missbrauchsverhindernde arzneimittelformulierungen
|
DE102004032049A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
GB2418854B
(en)
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
EP1786404A2
(de)
|
2004-09-01 |
2007-05-23 |
Euro-Celtique S.A. |
Opioid-dosierformen mit steady-state-cave proportional zur dosierung und auc und einzeldosen-cmax geringer als proportional zur dosierung
|
PT2767292T
(pt)
|
2004-09-17 |
2016-11-23 |
Durect Corp |
Composição anestésica local prolongada contendo aibs
|
US20080152595A1
(en)
*
|
2004-11-24 |
2008-06-26 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
US8481565B2
(en)
|
2004-12-27 |
2013-07-09 |
Eisai R&D Management Co., Ltd. |
Method for stabilizing anti-dementia drug
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
MX2007009162A
(es)
|
2005-01-28 |
2007-10-23 |
Euro Celtique Sa |
Formas de dosis rsistente al alcohol.
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1695700A1
(de)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Darreichungsform enthaltend Oxycodon und Naloxon
|
EP1702558A1
(de)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Verfahren und Vorrichtung zur Darmtätigkeitserfassung
|
US20060281775A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Applied Pharmacy Services, Inc. |
Two-component pharmaceutical composition for the treatment of pain
|
NZ561375A
(en)
|
2005-06-27 |
2011-06-30 |
Biovail Lab Int Srl |
Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
CN1957909B
(zh)
*
|
2005-10-31 |
2013-09-11 |
阿尔扎公司 |
降低鸦片样物质持续释放口服剂型的由醇诱导的剂量突然释放的方法
|
PL116330U1
(en)
*
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
EP1849460A3
(de)
*
|
2005-10-31 |
2007-11-14 |
ALZA Corporation |
Verfahren zur Reduktion der Alkohol induzierten Dosis Sturzentleerung oraler Zubereitungen mit verzögerter Freisetzung von Opioiden
|
US20100172989A1
(en)
*
|
2006-01-21 |
2010-07-08 |
Abbott Laboratories |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20090317355A1
(en)
*
|
2006-01-21 |
2009-12-24 |
Abbott Gmbh & Co. Kg, |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20090022798A1
(en)
*
|
2007-07-20 |
2009-01-22 |
Abbott Gmbh & Co. Kg |
Formulations of nonopioid and confined opioid analgesics
|
EP1993559B1
(de)
|
2006-02-03 |
2016-06-22 |
OPKO Renal, LLC |
Behandlug von vitamin-d-insuffizienz und -mangel mit 25-hydroxyvitamin d2 und 25-hydroxyvitamin d3
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
EP1995276A4
(de)
*
|
2006-03-15 |
2009-09-09 |
Johoku Chemical Co Ltd |
Stabilisiertes polyolefinharz und verfahren zur stabilisierung von polyolefinharz
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
US20070281016A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and surfactant
|
US20080069891A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
EP2484346B1
(de)
|
2006-06-19 |
2017-02-22 |
Alpharma Pharmaceuticals LLC |
Pharmazeutische Zusammensetzungen
|
EP2679228B1
(de)
|
2006-06-21 |
2018-03-21 |
Opko Ireland Global Holdings, Ltd. |
Therapie mit Vitamin-D-Sättigungsmittel und Vitamin-D-Hormonersatzmittel
|
ZA200900640B
(en)
*
|
2006-08-04 |
2010-06-30 |
Ethypharm Sa |
Granule and orally disintegrating tablet comprising oxycodone
|
EP2051740A4
(de)
*
|
2006-08-16 |
2010-01-13 |
Auspex Pharmaceuticals Inc |
Herstellung und verwendung von opioidanalgetika
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
PL2124556T3
(pl)
|
2006-10-09 |
2015-02-27 |
Charleston Laboratories Inc |
Kompozycje farmaceutyczne
|
ES2388355T3
(es)
|
2006-11-03 |
2012-10-11 |
Durect Corporation |
Sistemas de suministro transdémico que comprenden bupivacaína
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
EP3225243A1
(de)
|
2007-04-25 |
2017-10-04 |
Opko Renal, LLC |
Verfahren zur sicheren und effektiven behandlung und vorbeugung von sekundärem hyperparathyroidismus für chronische nierenerkrankung
|
HUE063590T2
(hu)
|
2007-04-25 |
2024-01-28 |
Eirgen Pharma Ltd |
Szabályozott felszabadulású 25-hidroxi-D-vitamin
|
DK2148684T3
(da)
|
2007-04-25 |
2013-04-22 |
Cytochroma Inc |
Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
|
US8202542B1
(en)
|
2007-05-31 |
2012-06-19 |
Tris Pharma |
Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
|
EP2155167A2
(de)
|
2007-06-04 |
2010-02-24 |
Egalet A/S |
Pharmazeutische zusammensetzungen mit gesteuerter freisetzung für verlängerte wirkung
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
US20080318994A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
|
US20080318993A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
|
DK2200593T5
(en)
*
|
2007-09-13 |
2016-12-12 |
Cima Labs Inc |
Hog-resistant pharmaceutical formulation
|
ATE455538T1
(de)
|
2007-11-09 |
2010-02-15 |
Acino Pharma Ag |
Retardtabletten mit hydromorphon
|
WO2009088414A2
(en)
|
2007-12-06 |
2009-07-16 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100266645A1
(en)
*
|
2007-12-17 |
2010-10-21 |
Alfred Liang |
Pharmaceutical compositions
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8124126B2
(en)
|
2008-01-09 |
2012-02-28 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
US8383152B2
(en)
|
2008-01-25 |
2013-02-26 |
Gruenenthal Gmbh |
Pharmaceutical dosage form
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
JP2011511782A
(ja)
|
2008-02-12 |
2011-04-14 |
アボット・ラボラトリーズ |
長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
|
KR101094231B1
(ko)
|
2008-02-18 |
2011-12-14 |
하나제약 주식회사 |
서방성 고형 제제 및 그의 제조방법
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
EP2262484B1
(de)
|
2008-03-11 |
2013-01-23 |
Depomed, Inc. |
Gastroretentive darreichungsformen mit verzögerter freisetzung mit komibinationen aus einem nichtopioiden analgetikum und einem opioiden analgetikum
|
ES2593356T3
(es)
|
2008-04-02 |
2016-12-07 |
Opko Ireland Global Holdings, Ltd. |
Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
|
US9449150B2
(en)
|
2008-04-24 |
2016-09-20 |
The Invention Science Fund I, Llc |
Combination treatment selection methods and systems
|
US8930208B2
(en)
*
|
2008-04-24 |
2015-01-06 |
The Invention Science Fund I, Llc |
Methods and systems for detecting a bioactive agent effect
|
US20090270688A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for presenting a combination treatment
|
US20100081860A1
(en)
*
|
2008-04-24 |
2010-04-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational System and Method for Memory Modification
|
US20100125561A1
(en)
*
|
2008-04-24 |
2010-05-20 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US9649469B2
(en)
*
|
2008-04-24 |
2017-05-16 |
The Invention Science Fund I Llc |
Methods and systems for presenting a combination treatment
|
US9239906B2
(en)
*
|
2008-04-24 |
2016-01-19 |
The Invention Science Fund I, Llc |
Combination treatment selection methods and systems
|
US20090312668A1
(en)
*
|
2008-04-24 |
2009-12-17 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US9282927B2
(en)
|
2008-04-24 |
2016-03-15 |
Invention Science Fund I, Llc |
Methods and systems for modifying bioactive agent use
|
US8876688B2
(en)
*
|
2008-04-24 |
2014-11-04 |
The Invention Science Fund I, Llc |
Combination treatment modification methods and systems
|
US20100042578A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20100130811A1
(en)
*
|
2008-04-24 |
2010-05-27 |
Searete Llc |
Computational system and method for memory modification
|
US9064036B2
(en)
*
|
2008-04-24 |
2015-06-23 |
The Invention Science Fund I, Llc |
Methods and systems for monitoring bioactive agent use
|
US9662391B2
(en)
*
|
2008-04-24 |
2017-05-30 |
The Invention Science Fund I Llc |
Side effect ameliorating combination therapeutic products and systems
|
US20100076249A1
(en)
*
|
2008-04-24 |
2010-03-25 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20100069724A1
(en)
*
|
2008-04-24 |
2010-03-18 |
Searete Llc |
Computational system and method for memory modification
|
US20100063368A1
(en)
*
|
2008-04-24 |
2010-03-11 |
Searete Llc, A Limited Liability Corporation |
Computational system and method for memory modification
|
US20100041964A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US20090269329A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination Therapeutic products and systems
|
US20090271122A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US20090271347A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring bioactive agent use
|
US20100041958A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc |
Computational system and method for memory modification
|
US20100280332A1
(en)
*
|
2008-04-24 |
2010-11-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring bioactive agent use
|
US20100081861A1
(en)
*
|
2008-04-24 |
2010-04-01 |
Searete Llc |
Computational System and Method for Memory Modification
|
US20100004762A1
(en)
*
|
2008-04-24 |
2010-01-07 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20090312595A1
(en)
*
|
2008-04-24 |
2009-12-17 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for memory modification
|
US20090271009A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination treatment modification methods and systems
|
US20090270694A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US20100022820A1
(en)
*
|
2008-04-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20100100036A1
(en)
*
|
2008-04-24 |
2010-04-22 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational System and Method for Memory Modification
|
US9026369B2
(en)
*
|
2008-04-24 |
2015-05-05 |
The Invention Science Fund I, Llc |
Methods and systems for presenting a combination treatment
|
US9560967B2
(en)
*
|
2008-04-24 |
2017-02-07 |
The Invention Science Fund I Llc |
Systems and apparatus for measuring a bioactive agent effect
|
US20100017001A1
(en)
*
|
2008-04-24 |
2010-01-21 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20090271375A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination treatment selection methods and systems
|
HUE030803T2
(en)
|
2008-05-09 |
2017-06-28 |
Gruenenthal Gmbh |
Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spraying step \ t
|
WO2009143209A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Qrxpharma Limited |
Dual opioid pain therapy
|
WO2010003963A1
(en)
*
|
2008-07-07 |
2010-01-14 |
Euro-Celtique S.A. |
Use of opioid antagonists for treating urinary retention
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
NZ594207A
(en)
|
2009-02-06 |
2013-03-28 |
Egalet Ltd |
Immediate release composition resistant to abuse by intake of alcohol
|
EP3045043B1
(de)
|
2009-02-26 |
2020-04-29 |
Relmada Therapeutics, Inc. |
Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
|
PL2405915T3
(pl)
|
2009-03-10 |
2019-05-31 |
Euro Celtique Sa |
Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
|
US8811578B2
(en)
*
|
2009-03-23 |
2014-08-19 |
Telemanager Technologies, Inc. |
System and method for providing local interactive voice response services
|
NZ603579A
(en)
|
2009-06-24 |
2014-02-28 |
Egalet Ltd |
Controlled release formulations
|
WO2011006012A1
(en)
|
2009-07-08 |
2011-01-13 |
Charleston Laboratories Inc. |
Pharmaceutical compositions
|
RU2555531C2
(ru)
*
|
2009-07-22 |
2015-07-10 |
Грюненталь Гмбх |
Защищенная от применения не по назначению лекарственная форма для чувствительных к окислению опиоидов
|
KR101738369B1
(ko)
|
2009-07-22 |
2017-05-22 |
그뤼넨탈 게엠베하 |
핫 멜트 압출된 제어 방출 투여형
|
US20110046173A1
(en)
*
|
2009-08-24 |
2011-02-24 |
Warren Charles Stern |
Combination analgesic opioid pain therapy
|
WO2011026125A2
(en)
*
|
2009-08-31 |
2011-03-03 |
Depomed, Inc. |
Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
|
EP3064064A1
(de)
*
|
2009-09-30 |
2016-09-07 |
Acura Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur abschreckung vor missbrauch
|
US20110104272A1
(en)
*
|
2009-11-05 |
2011-05-05 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US9579285B2
(en)
*
|
2010-02-03 |
2017-02-28 |
Gruenenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
EA029077B1
(ru)
*
|
2010-03-09 |
2018-02-28 |
Алкермес Фарма Айэленд Лимитед |
Устойчивая к спирту фармацевтическая лекарственная форма
|
CN105796530A
(zh)
|
2010-03-29 |
2016-07-27 |
赛特克罗公司 |
用于降低甲状旁腺水平的方法和组合物
|
EP2568977A1
(de)
|
2010-05-11 |
2013-03-20 |
Cima Labs Inc. |
Alkoholresistente metoprololhaltige orale retard-dosierformen
|
CA2801620A1
(en)
|
2010-07-06 |
2012-01-12 |
Gruenenthal Gmbh |
Novel gastro-retentive dosage forms comprising a gaba analog and an opioid
|
AR082862A1
(es)
|
2010-09-02 |
2013-01-16 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a alteracion que comprende un polimero anionico
|
EP2611426B1
(de)
|
2010-09-02 |
2014-06-25 |
Grünenthal GmbH |
Manipulationssichere darreichungsform mit einem anorganischen salz
|
EP2446882B8
(de)
|
2010-10-28 |
2014-02-12 |
Acino Pharma AG |
Arzneimittel mit dem Wirkstoff Hydromorphon mit verbesserter Lagerstabilität
|
EP2826468A1
(de)
|
2010-12-22 |
2015-01-21 |
Purdue Pharma L.P. |
Gekapselte manipulationssichere Darreichungsformen mit gesteuerter Freisetzung
|
CN103327969A
(zh)
|
2010-12-23 |
2013-09-25 |
普渡制药公司 |
抗篡改固体口服剂型
|
KR20130124551A
(ko)
|
2011-02-02 |
2013-11-14 |
알파마 파머슈티컬스 엘엘씨 |
오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
DK2688557T3
(da)
|
2011-03-23 |
2017-11-27 |
Ironshore Pharmaceuticals & Dev Inc |
Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
PL2726064T3
(pl)
*
|
2011-06-30 |
2017-06-30 |
Develco Pharma Schweiz Ag |
Doustna postać użytkowa o kontrolowanym uwalnianiu zawierająca oksykodon
|
AR087359A1
(es)
|
2011-07-29 |
2014-03-19 |
Gruenenthal Gmbh |
Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
|
EA201400172A1
(ru)
|
2011-07-29 |
2014-06-30 |
Грюненталь Гмбх |
Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
|
EP2819656A1
(de)
*
|
2012-02-28 |
2015-01-07 |
Grünenthal GmbH |
Fälschungssichere dosierform mit einer pharmazeutisch aktiven verbindung und einem anionischen polymer
|
WO2013153451A2
(en)
*
|
2012-04-09 |
2013-10-17 |
QRxPharma Ltd. |
Controlled release formulations of opioids
|
TW201811332A
(zh)
|
2012-04-17 |
2018-04-01 |
美商普渡製藥有限合夥事業 |
處理由類鴉片引起之不利的藥效動力反應之系統和方法
|
MX362357B
(es)
|
2012-04-18 |
2019-01-14 |
Gruenenthal Gmbh |
Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
CA2877183A1
(en)
|
2012-07-06 |
2014-01-09 |
Egalet Ltd. |
Abuse deterrent pharmaceutical compositions for controlled release
|
CA2877774C
(en)
|
2012-07-12 |
2017-07-18 |
Mallinckrodt Llc |
Extended release, abuse deterrent pharmaceutical compositions
|
EP3446685A1
(de)
|
2012-11-30 |
2019-02-27 |
Acura Pharmaceuticals, Inc. |
Selbstregulierende freisetzung eines pharmazeutischen wirkstoffs
|
KR101840526B1
(ko)
|
2013-02-05 |
2018-03-20 |
퍼듀 퍼머 엘피 |
내변조성 제약 제제
|
KR101847947B1
(ko)
|
2013-03-15 |
2018-05-28 |
옵코 아이피 홀딩스 Ⅱ 인코포레이티드 |
안정화되고 변형된 비타민 d 방출 제형
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US9572885B2
(en)
|
2013-03-15 |
2017-02-21 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
JP6445537B2
(ja)
|
2013-05-29 |
2018-12-26 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
1個または複数の粒子を含有する改変防止(tamper−resistant)剤形
|
AR096439A1
(es)
|
2013-05-29 |
2015-12-30 |
Gruenenthal Gmbh |
Forma de dosificación resistente al uso indebido que contiene una o más partículas
|
EA032465B1
(ru)
|
2013-07-12 |
2019-05-31 |
Грюненталь Гмбх |
Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
|
KR20180037074A
(ko)
|
2013-07-23 |
2018-04-10 |
유로-셀티큐 에스.에이. |
장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
|
US10195153B2
(en)
|
2013-08-12 |
2019-02-05 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
US20150118300A1
(en)
|
2013-10-31 |
2015-04-30 |
Cima Labs Inc. |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
|
AU2014356581C1
(en)
|
2013-11-26 |
2020-05-28 |
Grunenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
CA2943728C
(en)
|
2014-03-26 |
2020-03-24 |
Sun Pharma Advanced Research Company Ltd. |
Abuse deterrent immediate release biphasic matrix solid dosage form
|
AU2015261060A1
(en)
|
2014-05-12 |
2016-11-03 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising Tapentadol
|
CA2949422A1
(en)
|
2014-05-26 |
2015-12-03 |
Grunenthal Gmbh |
Multiparticles safeguarded against ethanolic dose-dumping
|
TW202136296A
(zh)
|
2014-06-27 |
2021-10-01 |
美商C2N醫療診斷有限責任公司 |
人類化抗-tau抗體
|
EP3169315B1
(de)
|
2014-07-17 |
2020-06-24 |
Pharmaceutical Manufacturing Research Services, Inc. |
Missbrauchssichere flüssigkeitsfülldosierform mit unmittelbarer freisetzung
|
NZ728823A
(en)
|
2014-08-07 |
2024-01-26 |
Opko Ireland Global Holdings Ltd |
Adjunctive therapy with 25-hydroxyvitamin d
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
US20160106737A1
(en)
|
2014-10-20 |
2016-04-21 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended Release Abuse Deterrent Liquid Fill Dosage Form
|
CA2936748C
(en)
|
2014-10-31 |
2017-08-08 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
EP3285745A1
(de)
|
2015-04-24 |
2018-02-28 |
Grünenthal GmbH |
Manipulationssichere darreichungsform mit sofortiger freisetzung und widerstand gegen lösungsmittelextraktion
|
US11103581B2
(en)
|
2015-08-31 |
2021-08-31 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
US9861629B1
(en)
|
2015-10-07 |
2018-01-09 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
JP2019507181A
(ja)
|
2016-03-04 |
2019-03-14 |
チャールストン ラボラトリーズ,インコーポレイテッド |
医薬組成物
|
JP7032322B2
(ja)
|
2016-03-28 |
2022-03-08 |
オプコ アイルランド グローバル ホールディングス リミテッド |
ビタミンd治療法
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
WO2017222575A1
(en)
|
2016-06-23 |
2017-12-28 |
Collegium Pharmaceutical, Inc. |
Process of making more stable abuse-deterrent oral formulations
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
EP3703724A1
(de)
|
2017-11-02 |
2020-09-09 |
NatureCeuticals Sdn. Bhd. |
Extrakt aus orthosiphon stamineus, formulierungen und verwendungen davon
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2020225773A1
(en)
|
2019-05-07 |
2020-11-12 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
CN115666621A
(zh)
|
2020-01-13 |
2023-01-31 |
度勒科特公司 |
具有减少的杂质的持续释放药物递送系统及相关方法
|
CN115702888A
(zh)
*
|
2021-08-13 |
2023-02-17 |
合肥立方制药股份有限公司 |
一种盐酸羟考酮渗透泵缓释片及其制备方法
|